Worth reading
7Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
20000000
Yen (maximum impact on results)Wording
Conditional
How definitive the wording is.Items stated in the management plan
Key initiatives
01Establishment of an integrated platform for the development of regenerative medicine products using AI/DX
Plan assumptionsThe regenerative and cellular medicine sector, a growing and expanding market
| Item | Details |
|---|---|
| Plan name | FY2026 Social Impact Project |
| Plan period | Fiscal 2026 |
| Plan assumptions | The regenerative and cellular medicine sector, a growing and expanding market |
| Key initiatives | Establishment of an integrated platform for the development of regenerative medicine products using AI/DX |
| Publication date | 15 July 2026 |
Items this document does not state (20)
Progress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen product development capabilities and the business foundation through enhanced collaboration with the community, and to accelerate activities aimed at expanding the bio community and developing the biotechnology industry.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.